Drug Profile
Research programme: malaria vaccines - IMV/Leidos
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Immunovaccine; Leidos Holdings
- Developer IMV; Leidos Holdings
- Class Antimalarials; Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Malaria in Canada (unspecified route)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Malaria in Canada
- 03 May 2018 Immunovaccine is now called IMV